Free Trial
NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

$0.10 -0.01 (-6.24%)
Closing price 01:15 PM Eastern
Extended Trading
$0.10 0.00 (0.00%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Jasper Therapeutics Stock (NASDAQ:JSPRW)

Key Stats

Today's Range
$0.09
$0.11
50-Day Range
$0.08
$0.15
52-Week Range
$0.06
$0.25
Volume
1,249 shs
Average Volume
7,517 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPRW Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Jasper Therapeutics (JSPR) Gets a Buy from UBS
Jasper Therapeutics (JSPR) Receives a Buy from Credit Suisse
See More Headlines

JSPRW Stock Analysis - Frequently Asked Questions

Jasper Therapeutics' stock was trading at $0.2096 at the start of the year. Since then, JSPRW stock has decreased by 54.2% and is now trading at $0.0961.
View the best growth stocks for 2025 here
.

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JSPRW
Web
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:JSPRW) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners